Evaluation of Downstream Regulatory Element Antagonistic Modulator Gene in Human Multinodular Goiter

Carregando...
Imagem de Miniatura
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
INT SCIENTIFIC LITERATURE, INC
Citação
MEDICAL SCIENCE MONITOR BASIC RESEARCH, v.21, p.179-182, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: DREAM (Downstream Regulatory Element Antagonistic Modulator) is a neuronal calcium sensor that was suggested to modulate TSH receptor activity and whose overexpression provokes an enlargement of the thyroid gland in transgenic mice. The aim of this study was to investigate somatic mutations and DREAM gene expression in human multinodular goiter (MNG). Material/Methods: DNA and RNA samples were obtained from hyperplastic thyroid glands of 60 patients (54 females) with benign MNG. DREAM mutations were evaluated by PCR and direct automatic sequencing, whereas relative quantification of mRNA was performed by real-time PCR. Over-and under-expression were defined as a 2-fold increase and decrease in comparison to normal thyroid tissue, respectively. RQ M (relative quantification mean); SD (standard deviation). Results: DREAM expression was detected in all nodules evaluated. DREAM mRNA was overexpressed in 31.7% of MNG (RQ M=6.26; SD=5.08), whereas 53.3% and 15% had either normal (RQ M=1.16; SD=0.46) or underexpression (RQ M=0.30; SD=0.10), respectively. Regarding DREAM mutations analysis, only previously described intronic polymorphisms were observed. Conclusions: We report DREAM gene expression in the hyperplastic thyroid gland of MNG patients. However, DREAM expression did not vary significantly, and was somewhat underexpressed in most patients, suggesting that DREAM upregulation does not significantly affect nodular development in human goiter.
Palavras-chave
DNA Mutational Analysis, Gene Expression, Goiter, Nodular, Kv Channel-Interacting Proteins
Referências
  1. Baczyk D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051837
  2. Brix TH, 1999, J CLIN ENDOCR METAB, V84, P3071, DOI 10.1210/jc.84.9.3071
  3. Carrion AM, 1999, NATURE, V398, P80
  4. D'Andrea B, 2005, EXP CELL RES, V305, P166, DOI 10.1016/j.yexcr.2004.12.012
  5. Derwahl M, 1998, THYROID CANC, P155
  6. Krohn K, 2005, ENDOCR REV, V26, P504, DOI 10.1210/er.2004-0005
  7. Ledo F, 2002, EMBO J, V21, P4583, DOI 10.1093/emboj/cdf440
  8. Ledo F, 2000, MOL CELL BIOL, V20, P9120, DOI 10.1128/MCB.20.24.9120-9126.2000
  9. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  10. Matsuda M, 2006, ENDOCRINOLOGY, V147, P4608, DOI 10.1210/en.2006-0254
  11. Medeiros-Neto G, 2000, ENDOTEXT, P1
  12. Pinchera A., 1996, Annali Italiani di Chirurgia, V67, P317
  13. Rivas M, 2004, J BIOL CHEM, V279, P33114, DOI 10.1074/jbc.M403526200
  14. Rivas M, 2009, MOL ENDOCRINOL, V23, P862, DOI 10.1210/me.2008-0466
  15. Savignac M, 2005, EMBO J, V24, P3555, DOI 10.1038/sj.emboj.7600810
  16. Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596